3-methoxytyrosine has been researched along with Hallucinations in 1 studies
Hallucinations: Subjectively experienced sensations in the absence of an appropriate stimulus, but which are regarded by the individual as real. They may be of organic origin or associated with MENTAL DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the patient group with visual hallucinations, mean salsolinol level was significantly increased to almost the 3-fold of those found in patients without hallucinations." | 5.29 | Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease. ( Jaskowski, P; Kömpf, D; Moser, A; Siebecker, F; Vieregge, P, 1996) |
| "In the patient group with visual hallucinations, mean salsolinol level was significantly increased to almost the 3-fold of those found in patients without hallucinations." | 1.29 | Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease. ( Jaskowski, P; Kömpf, D; Moser, A; Siebecker, F; Vieregge, P, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moser, A | 1 |
| Siebecker, F | 1 |
| Vieregge, P | 1 |
| Jaskowski, P | 1 |
| Kömpf, D | 1 |
1 other study available for 3-methoxytyrosine and Hallucinations
| Article | Year |
|---|---|
Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Biomarkers; Catecholamines; Female; Hallucinations | 1996 |